drugset / Trial / NCT06617182

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

NCT06617182

Phase 2 Recruiting 150 enrolled Yongquan Shi
RandomizedParallel-groupOpen-labelTreatment

Summary

At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.

Timeline

Start
2024-09-30
Primary completion
2028-10-01
Completion
2028-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Glutamine Other / unclassified Oral
Subject Thalidomide Other / unclassified 100 mg Oral

Indications